Achieve Life Sciences ACHV Proceeds from maturities of marketable securities

Proceeds from maturities of marketable securities at other companies

EyePoint, Inc. EYPT

$80.93M+76.9%

AbCellera Biologics Inc.ABCL

$143.8M-24.3%

KEE

Keel Infrastructure Corp. Common StockKEEL

$989K-85.7%

NextNavNN

$84M+143%

ZymeworksZYME

$70.18M+50.7%

Oruka Therapeutics, Inc.ORKA

$76.47M-12.3%

Other financials

Income statement

See full

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Balance sheet

See full

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Cash flow

See full

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Valuation

See full

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Returns & leverage

See full

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Where this comes from

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's proceeds from maturities of marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Achieve Life Sciences's proceeds from maturities of marketable securities?: Achieve Life Sciences (ACHV) reported proceeds from maturities of marketable securities of $15.43M in Q1 2026.